Dificid Suspension (fidaxomicin susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Dificid Suspension (fidaxomicin susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Clostridium difficile infection				
□ Other DiagnosisICD-10 Co				
	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.				
Clinical information:				
Is patient using drug as part of a clinica	al trial? 🗆 Yes 🗆 No			
		- N		
-	icile toxin present in the stool? 🗆 Yes 🛛	□ NO		
Please provide documentation.				
Mos the nations started on Dificid the	envin en innetient setting? - Ves N			
was the patient started on Dificia ther	rapy in an inpatient setting? 🗆 Yes 🗆 N	10		
Was the patient started on Dificid therapy in an outpatient setting? \Box Yes \Box No				
-	t ONE of the following therapies? <pre>□</pre> Yes	s 🗆 No Please provide		
documentation.				
□ Vancocin (vancomycin)				
🗆 Xifaxan (rifaximin)				
Flagyl (metronidazole)				
	.			
Is the patient on enteral feedings?	es 🗆 No			
Does the patient have difficulty swallowing? Yes No				
Is the notion taking other and tablet or conculo medications $2 - N_{con} = N_{con}$				
Is the patient taking other oral tablet or capsule medications? Yes No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the				
physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required				
information is received.				
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that				
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
mormation necessary to verify the acc	uracy of the information reported on thi	s iorm.		
	Marifiantian.	Data		
Prescriber Signature or Electronic I.D.	Verification:	Date:		



Dificid Suspension (fidaxomicin susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

